The latest findings from the EMPA-REG OUTCOME trial show a 34% reduction in hospitalization for heart failure or cardiovascular death in patients receiving empagliflozin, a sodium/glucose cotransporter 2 (SGLT2) inhibitor, compared with placebo. These outstanding results call for discussion of the clinical implications, and in-depth studies of the mechanisms of action of SGLT2 inhibitors.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bertoni, A. G. et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 27, 699–703 (2004).
Gilbert, R. E. & Krum, H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 23, 2107–2117 (2015).
Fitchett, D. et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/ehv728, (2016).
Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K. & Laakso, M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339, 229–234 (1998).
Komoroski, B. et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin. Pharmacol. Ther. 85, 520–526 (2009).
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B. & List, J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes. Metab. 15, 853–862 (2013).
Oh, J. et al. Hemoconcentration is a good prognostic predictor for clinical outcomes in acute heart failure: data from the Korean Heart Failure (KorHF) Registry. Int. J. Cardiol. 168, 4739–4743 (2013).
Abdel-Qadir, H. M. et al. Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. Am. Heart J. 160, 264–271.e1 (2010).
Wanner, C. Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease. Presented at the American Society of Nephrology (ASN) Kidney Week (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
I.R. declares that he is an Advisory Board member for AstraZeneca/Bristol–Meyers Squibb, Boehringer Ingelheim, Eli Lilly, Labstyle Innovations, Merck, Novo Nordisk, Orgenesis, Sanofi, and SmartZyme Innovation; that he is a consultant for AstraZeneca/Bristol–Meyers Squibb, the Diabetes Medical Center (Tel Aviv, Israel), FuturRx, Insuline Medical, Gili Medical, Kamada, and Nephrogenex; that he is in the Speaker's Bureau of AstraZeneca/Bristol–Meyers Squibb, Boehringer Ingelheim, Eli Lilly, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Sanofi, and Teva; and that he is a stock/shareholder of Glucome, Insuline Medical, Labstyle Innovations, Orgenesis, and SmartZyme Innovation. A.C. declares that she has received consulting fees and payment for lectures from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Novo Nordisk, and Sanofi.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Raz, I., Cahn, A. SGLT2 inhibitors and heart failure — clinical implications. Nat Rev Cardiol 13, 185–186 (2016). https://doi.org/10.1038/nrcardio.2016.35
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2016.35
This article is cited by
-
Pharmacologic and interventional paradigms of diuretic resistance in congestive heart failure: a narrative review
International Urology and Nephrology (2021)
-
Looking back and thinking forwards — 15 years of cardiology and cardiovascular research
Nature Reviews Cardiology (2019)
-
Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study
Diabetologia (2018)
-
Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line
Cardiovascular Drugs and Therapy (2017)
-
SGLT2 Inhibitors: Benefit/Risk Balance
Current Diabetes Reports (2016)